AstraZeneca's cancer drug fails to meet main goal in COVID-19 trials

The drugmaker called the results from the study disappointing but said it remained committed to its clinical trials for its COVID-19 vaccine, developed in partnership with Oxford University, and its long-acting antibody combination.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3lpufiq
via IFTTT